Ghent University Academic Bibliography

Journal Article
A1
open access

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia

André Pedro Pinto De Almeida (UGent) , Sara T'Sas (UGent) , Luca Pagliaro (UGent) , Igor Fijalkowski (UGent) , Wouter Sleeckx (UGent) , Hannah Van Steenberge (UGent) , Raffaella Zamponi, Béatrice Lintermans (UGent) , Wouter Van Loocke (UGent) , Bruno Palhais (UGent) , et al.

(2024) HEMASPHERE. 8(3).

Add to list

Journal Article
A1
open access

Flow cytometry interference in patients treated with tafasitamab : unraveling the diagnostic maze

Lisa Proost, Stijn Lambrecht (UGent) , Mattias Hofmans (UGent) , Ciel De Vriendt (UGent) , Marijn Speeckaert (UGent) , Carolien Bonroy (UGent) , Barbara Denys (UGent) and Sander De Bruyne (UGent)

(2024) HEMASPHERE. 8(1).

Add to list

Journal Article
A1
open access

CAR-T in the treatment of acute myeloid leukemia : barriers and how to overcome them

Jolien Vanhooren (UGent) , Rani Dobbelaere, Charlotte Derpoorter (UGent) , Larissa Deneweth (UGent) , Laurens Van Camp (UGent) , Anne Uyttebroeck, Barbara De Moerloose (UGent) and Tim Lammens

(2023) HEMASPHERE. 7(9).

Add to list

Journal Article
A1
open access

Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma

Roch Houot, Viola Poeschel, Bettina Altmann, Stephanie Angel, Lorenz Thurner, Thomas Illmer, Marc Andre, Martin Dreyling, Herve Maisonneuve, Herve Tilly, et al.

(2022) HEMASPHERE. 6(2).

Add to list

Journal Article
A1
open access

Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine : an EPICOVIDEHA report

J Salmanton-García, F Marchesi, A Glenthøj, YM Bilgin, Jens Van Praet (UGent) , J Dávila-Valls, S Martín-Pérez, J Labrador, J van Doesum, I Falces-Romero, et al.

(2022) HEMASPHERE. 6(11).

Add to list

Journal Article
A1
open access

Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia : experience of the European LeukemiaNet MRD Working Party

Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippé (UGent) , et al.

(2022) HEMASPHERE. 6(1).

Add to list

Journal Article
A1
open access

Clinical significance of TARP expression in pediatric acute myeloid leukemia

Barbara Depreter, Barbara De Moerloose (UGent) , Karl Vandepoele (UGent) , Anne Uyttebroeck, An Van Damme, Barbara Denys, Laurence Dedeken, Marie-Françoise Dresse, Jutte Van Der Werff Ten Bosch, Mattias Hofmans (UGent) , et al.

(2020) HEMASPHERE. 4(2).

Add to list

Conference Paper
C3
open access

TARP as immunotherapeutic target in AML expressed in the LSC compartment

Barbara Depreter, Karin Weening (UGent) , Karl Vandepoele (UGent) , M Essand, Barbara De Moerloose (UGent) , M Themeli, J Cloos, D Hanekamp, Ine Moors (UGent) , Inge D'hont (UGent) , et al.

(2019) HEMASPHERE. 3(suppl. 1). p.54-54

Add to list

Journal Article
A2
open access

ZEB proteins in leukemia : friends, foes, or friendly foes?

Bieke Soen (UGent) , Niels Vandamme (UGent) , Geert Berx (UGent) , Jürg Schwaller, Pieter Van Vlierberghe (UGent) and Steven Goossens (UGent)

(2018) HEMASPHERE. 2(3).

Academic Bibliography

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia

Flow cytometry interference in patients treated with tafasitamab : unraveling the diagnostic maze

CAR-T in the treatment of acute myeloid leukemia : barriers and how to overcome them

Prolonged remissions after nivolumab plus gemcitabine/oxaliplatin in relapsed/refractory T-cell lymphoma

Improved clinical outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine : an EPICOVIDEHA report

Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia : experience of the European LeukemiaNet MRD Working Party

Clinical significance of TARP expression in pediatric acute myeloid leukemia

TARP as immunotherapeutic target in AML expressed in the LSC compartment

ZEB proteins in leukemia : friends, foes, or friendly foes?

Contents

Support

Contact